Notes on ESMO17: Health economics

Clinical Brief – September 25th

ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.


A study led by researchers from Turkey found that over 90% of their patients taking a targeted cancer treatment was also on another prescription med. More than half of these patients had a drug-drug interaction involving their cancer treatment.

Drug-drug interactions happen when Continue reading “Notes on ESMO17: Health economics”

Notes on ESMO17: Melanoma

Clinical Brief – September 22nd

ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.


Active surveillance after surgery for uveal melanoma can help detect resectable liver metastases.

Researchers from the St Vincent’s University Hospital, Ireland, tested Continue reading “Notes on ESMO17: Melanoma”

Notes on ESMO17: Palliative oncology

Clinical Brief – September 21st

ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.


Chemo is often dosed based on a person’s body-surface area. However, giving someone chemo based on how much drug the body actually gets instead, or pharmacokinetic-guided dosing, may help optimize the dose and reduce severe toxicities. Continue reading “Notes on ESMO17: Palliative oncology”

Notes on ESMO17: Metastatic lung cancer

Clinical Brief – September 20th

ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.


“Hyper-progressive disease is frequent in non-small cell lung cancer after treatment with anti-PD-1/PD-L1 immunotherapy,” reports a study led by researchers at Gustave Roussy, France. Continue reading “Notes on ESMO17: Metastatic lung cancer”

The week in brief

September 11th – 15th

Hi there, hope you had a great week! Here are your recent updates in the world of medical research and policy.


Lazy eye is a childhood condition where vision in one eye doesn’t develop properly.

The USPSTF now recommends screening kids between 3 to 5 years old at least once for lazy eye or its risk factors (USPSTF = US Preventive Services Task Force).


Researchers at the Mayo Clinic published a report on how they managed 10 patients who experienced immune-mediated neurological side effects after treatments with nivolumab (Opdivo) or pembrolizumab (Keytruda).

Reports like these teach us more about the possible harms of immunotherapies and balances the studies that are designed to show their efficacies.


ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.

Hematology

  • Treatment with radioactive iodine may be linked to the risk of developing acute myeloid leukemia, or AML.
  • Benefits of relatively modern treatments may benefit both younger and older patients with relapsed and refractory multiple myeloma.
  • Infusion-related reactions to daratumumab (Darzalex) may be managed with pre- and post-infusion meds.
  • Autologous stem cell transplantation may be considered for patients with non-Hodgkin lymphoma who are over 65.
  • Screening patients for multi-drug resistant bacteria may help predict sepsis involving such bacteria after chemotherapy.

Cancer prevention and screening

  • A social experiment looked at how citizen’s jury may handle decisions on policy about breast cancer screening.
  • A report summarized clinical features and outcomes of a serious but rare neurological side effect linked to treatment with bevacizumab (Avastin).
  • Cervical cancer screening is on the decline in France.
  • H. pylori infection may be linked to increased risk of stomach cancer in Japan.
  • Colorectal cancer is the 3rd most common cancer in Iran, but public awareness may be lagging behind.

Head and neck cancer

  • EBV viral load may be used to assess the risk of relapse and worse disease outcomes for non-metastatic nasopharyngeal carcinoma (a rare type of head and neck cancer).
  • Researchers from two cancer centers in Spain looked at their patients on immunotherapies in search for signs of hyper progression.
  • Collaboration between oncologists and geriatricians may help optimize treatment for elderly patients with head and neck cancer.
  • Radiation with high-dose chemo isn’t necessarily better than with low-dose chemo for head and neck cancer.

 

Like what you see? Subscribe to the newsletter below, and drop by Twitter to say ‘hi’ 🤓.

 

Notes on ESMO17: Head and neck cancer

Clinical Brief – September 15th

ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.


EBV viral load may be used to assess the risk of relapse and worse disease outcomes for non-metastatic nasopharyngeal carcinoma (a rare type of head and neck cancer). Continue reading “Notes on ESMO17: Head and neck cancer”

Notes on ESMO17: Cancer prevention and screening

Clinical Brief – September 14th

ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.


Should cancer screening policy be set by a citizen’s jury?

In a social experiment, researchers from Spain recruited 13 women to help decide whether Andalucía’s Public Health System should offer screening mammography for women between 50 and 69. Continue reading “Notes on ESMO17: Cancer prevention and screening”

Notes on ESMO17: Hematology

Clinical Brief – September 13th

ESMO, or the European Society of Medical Oncology Congress, is an annual gathering of cancer experts and patient advocates. Here are some studies from this year’s ESMO that may be of use.


Treatment with radioactive iodine may be linked to the risk of developing acute myeloid leukemia, or AML. Continue reading “Notes on ESMO17: Hematology”

Cases: Neurological complications linked to anti-PD-1 immunotherapies

Clinical Brief – September 12th

The Brief

Last week, researchers at the Mayo Clinic published a report on how they managed 10 patients who experienced immune-mediated neurological side effects after treatments with nivolumab (Opdivo) or pembrolizumab (Keytruda).

Reports like these teach us more about the possible harms of immunotherapies and balances the studies that are designed to show their efficacies. Continue reading “Cases: Neurological complications linked to anti-PD-1 immunotherapies”